Table 4.

Description about the list of clinical trials taken from https://www.clinicaltrials.gov/.

PathologicalCondition	Enrolled Patients	Intervention	National Clinical Trial Number	Outcome Measures	Phase	Status
Autologous mesenchymal stromal cell	24	Autologous mesenchymal stromal cell	NCT02384018	C-peptide level, liver function, kidney function, absence of severe hypoglycemic episodes	Phase 1	Ongoing
T2DM With Renal Manifestations	54	Human umbilical cord mesenchymal stem cells	NCT04216849	Estimated glomerular filtration rate, urinary albumin creatinine ratio	Phase 2	Ongoing
Diabetic Nephropathy	15	Human umbilical cord mesenchymal stem cells	NCT04125329	Incidence of treatment-emergent, treatment-chronic adverse events and estimated glomerular filtration rate	Early Phase 1	Ongoing
Diabetic Nephropathies	20	Wharton Jelly Mesenchymal stem cells	NCT03288571	Incidence of treatment-emergent adverse events, glomerular filtration rate, and protein to creatinine ratio	Phase 2	Ongoing
Diabetic Kidney Disease	48	Mesenchymal Stromal Cells	NCT02585622	Adverse events, glomerular filtration rate, urinary albumin/creatinine ratio, urinary albumin excretion, fasting blood glucose, and fasting blood glucose	Phase 2	Ongoing
T1DM	20	Intravenous Injection of autologous mesenchymal stem cells	NCT04078308	Baseline fasting blood sugar (FBS), assessing fasting blood sugar (FBS), C-peptide concentration, and Insulin uptake	Phase 2	Ongoing
T2DM	30	Expanded autologous bone marrow-derived mesenchymal stem cell	NCT03343782	Insulin dose, adverse events, and hemoglobin A1c (HbA1c) level	Phase 2	Completed
T1DM	20	Mesenchymal stem cells	NCT01068951	C-peptide concentration	NA	Completed
T2DM	200	Umbilical cord mesenchymal stem cells	NCT02302599	Change from baseline in fasting glucose over time	Phase 1	Completed